COMMUNIQUÉS West-GlobeNewswire

-
Nu-Med Plus Announces Keith L. Merrell as their full-time Chief Financial Officer and Secretary/Treasurer
13/02/2018 -
Progressive Care Breaks Record with Over 23,000 Prescriptions Filled in January 2018
13/02/2018 -
Pain Therapeutics Resubmits New Drug Application for REMOXY® ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain
13/02/2018 -
Tyme to Present at RBC Capital Markets 2018 Global Healthcare Conference
13/02/2018 -
PositiveID’s Thermomedics Delivers First 500 Caregiver Bluetooth Thermometers to Global Healthcare Company
13/02/2018 -
Connexion Health Launches by Unveiling a Health and Fitness Platform for the 21st Century; Sacramento Kings Are First NBA Team to Announce Use of High-Tech Kiosk
13/02/2018 -
Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
13/02/2018 -
Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage
13/02/2018 -
Annual General Meeting in ALK-Abelló A/S on 12 March 2018
13/02/2018 -
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
13/02/2018 -
KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference
13/02/2018 -
OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
13/02/2018 -
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1
13/02/2018 -
Shire Provides Regulatory Progress Update for Key Pipeline Programs Targeting Rare Disease
13/02/2018 -
RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018
13/02/2018 -
CampDoc.com Partners with CCC to Offer Integrated Camp Electronic Health Record Solution
13/02/2018 -
Natus to Present at Raymond James 39th Annual Institutional Investors Conference
13/02/2018 -
Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics & Biosimilars Congress Europe (March 2018)
13/02/2018 -
Initiation of stock buyback program
13/02/2018
Pages